Aarge Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 22-12-2024
- Paid Up Capital ₹ 3.75 M
as on 22-12-2024
- Company Age 48 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.47 M
as on 22-12-2024
- Satisfied Charges ₹ 2.31 M
as on 22-12-2024
- Revenue -99.95%
(FY 2023)
- Profit -180.57%
(FY 2023)
- Ebitda -27.09%
(FY 2023)
- Net Worth -45.18%
(FY 2023)
- Total Assets -45.71%
(FY 2023)
About Aarge Drugs
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 3.75 M.
The company currently has active open charges totaling ₹0.47 M. The company has closed loans amounting to ₹2.31 M, as per Ministry of Corporate Affairs (MCA) records.
Ravi Goel and Ravinder Goel serve as directors at the Company.
- CIN/LLPIN
U24231HP1976PTC003625
- Company No.
003625
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Feb 1976
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Himachal Pradesh
Industry
Company Details
- Location
Solan, Himachal Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Aarge Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravinder Goel  | Managing Director | 06-Feb-1976 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ravi Goel | Director | 06-Feb-1976 | Current |
Financial Performance of Aarge Drugs.
Aarge Drugs Pvt Ltd, for the financial year ended 2023, experienced significant reduction in revenue, with a 99.95% decrease. The company also saw a substantial fall in profitability, with a 180.57% decrease in profit. The company's net worth observed a substantial decline by a decrease of 45.18%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aarge Drugs?
Unlock access to Aarge Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 18 Mar 1992 | ₹0.47 M | Open |
State Bank Of India Creation Date: 02 Mar 2004 | ₹0.75 M | Satisfied |
State Bank Of India Creation Date: 18 Mar 1992 | ₹0.10 M | Satisfied |
How Many Employees Work at Aarge Drugs?
Unlock and access historical data on people associated with Aarge Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aarge Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aarge Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
